A review of the effects of transurethral microwave thermotherapy (TUMT) for lower urinary tract symptoms (LUTS) in men with benign prostate hyperplasia

Roger Ziętek, Zbigniew Ziętek


In the last decade of the new millennium, it can be seen that the number of transurethral microwave thermotherapy (TUMT) treatments has decreased significantly. Investigating the reasons for this trend, it was decided to review the literature data on TUMT. This review mainly focuses on the effectiveness of TUMT on lower urinary tract symptoms (LUTS) and the impact on erectile function (EF). The reference method was transurethral resection of the prostate (TURP). MEDLINE, EMBASE, Scopus and Cochrane Library databases between 1991–2021 were searched to identify studies on TUMT. The review included both randomized controlled trials and non-randomized trials; 55 items were selected for further analysis. They included 13 randomized reports, 1 non-randomized report and 8 reviews. Surprisingly, data analysis shows that TUMT is almost as effective in reducing LUTS as TURP. However, significant differences in complication profiles were noted. Transurethral microwave thermotherapy showed negligible morbidity and no serious complications compared to TURP. Transurethral microwave thermotherapy is also characterized by a slight influence on erectile dysfunction and retrograde ejaculation in contrast to TURP. Two facts of TUMT draw attention: the lack of precise qualification criteria and too few randomized controlled trials. Despite the critical attitude of some researchers to TUMT, it seems to be a valuable method and a suitable alternative to TURP. However, further research is needed with an increasing number of randomized controlled trials. This review aims to discuss the effects on EF of TUMT for LUTS in men with benign prostate hyperplasia.


erectile dysfunction; transurethral microwave thermotherapy; TUMT; lower urinary tract symptoms; LUTS; benign prostate hyperplasia; complications, revie

Full Text:



Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”. Eur Urol 2003;44(5):588-94.

de la Rosette JJ, Laguna MP, Gravas S, de Wildt MJAM. Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies or patients with benign prostatic hyperplasia? J Endourol 2003;17(4):245-51.

Walmsley K, Kaplan SA. Transurethral microwave thermotherapy for benign prostate hyperplasia: separating truth from marketing hype. J Urol 2004;172:1249-55. doi: 10.1097/01.ju.0000129967.30558.ca.

Hoffman RM, Monga M, Elliot SP, Mac Donald R, Langsjoen J, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane database of systematic reviews. The Cochrane Library; 2012. p. 9.

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46(5):547-54.

Madersbacher S, Marberger M. Is transurethral resection of the prostatę still justified? BJU Int 1999;83(3):227-37.

Madersbacher S, Kratzik C, Susani M, Marberger M. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 1994;152(6 Pt 1):1956-60.

Nørby B, Nielsen HV, Frimodt-Møller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs. transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 2002;90(9):853-62.

Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur Urol 2006;50(5):969-80.

Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008;180(1):246-9.

Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008;180(1):241-5.

Tzortzis V, Gravas S, de la Rosette JJMCH. Minimally invasive surgical treatments for benign prostatic hyperplasia Eur Urol Suppl 2009;8(6):513-22.

Dixon C, Rijo Cedano E, Pacik D, Vit V, Varga G, Wagrell L, et al. Transurethral water vapor therapy for BPH; initial clinical results of the first in man trial and Rezum I pilot study. Eur Urol Suppl 2013;12:e631.

Chung A, Woo HH. What’s truly minimally invasive in benign prostatic hyperplasia surgery? Curr Opin Urol 2014;24(1):36-41.

Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I, et al. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 2015;29(1):63-9.

Schade GR, Styn NR, Hall TL, Roberts WW. Endoscopic assessment and prediction of prostate urethral disintegration after histotripsy treatment in a canine model. J Endourol 2012;26(2):183-9.

Tabatabaei S, Zangi M. Outpatient surgery for lower urinary tract symptoms/benign prostatic hyperplasia: truth or myth? Curr Opin Urol 2015;25:27(1)-31. doi: 10.1097/MOU.0000000000000127.

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98.

Aagaard MF, Niebuhr MH, Jacobsen JD, Nielsen KK. Transurethral microwave thermotherapy treatment of chronic urinary retention in patients unsuitable for surgery. Scand J Urol 2014;48:290-4.

Ravery V. Transurethral microwave thermotherapy v transurethral resection of prostate. J Endourol 2000;14:693-6. doi: 10.1089/end.2000.14.693.

Brehmer M, Baba S: Transurethral microwave thermotherapy, how does it work? J Endourol 2000;14(8):611-5.

Yerushalmi A, Fishelovitz Y, Singer D, Reiner I, Arielly J, Abramovici Y, et al. Localized deep microwave hyperthermia in the treatment of poor operative risk patients with benign prostatic hyperplasia. J Urol 1985;133(5):873-6.

Veselys S, Muller M, Knutson T, Peeker R, Hellström M, Dahlstrand C. Tranurethral microwave thermotherapy of the prostate – Evaluation with MRI and analysis of parameters relevant to outcome. Scand J Urol Nephrol 2008;42(1):53-8.

Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guidelines; 2019.

Wilhelm K. Benign prostatic hyperplasia: possibilities of microwave thermotherapy. Der Urologe 2018;57:1366-9. doi: 10.1007/s00120-018-0779-z.

Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997;79(2):181-5.

AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530-47.

Lerner LB, McVary, KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. J Urol 2021;206(4):818-26. doi: 10.1097/JU.0000000000002183.

Lerner LB, McVary, KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part II, surgical evaluation and treatment. J Urol 2021;206(4):806-17. doi: 10.1097/JU.0000000000002184.

Franco JVA, Garegnani L, Escobar Liquitay CM, Borofsky M, Dahm P. Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. World J Mens Health 2021;39(6):CD004135. doi: 10.1002/14651858.CD004135.pub4.

Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76(3):325-36.

Perlmutter AP, Perachino M. Mechanism of microwave thermotherapy. World J Urol 1998;16(2):82-8.

D’Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. J Urol 1997;158:120-5. doi:10.1097/00005392-199707000-00035.

Mattiasson A, Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Randomized Controlled Trial. Urology 2007;69(1):91-6. doi: 10.1016/j. urology.2006.08.1115.

Dahlstrand C, Geirsson G, Fall M, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for benign prostatic hyperplasia: preliminary results of a randomized study. Eur Urol 1993;23(2):292-8. doi: 10.1159/000474615.

Ogden CW, Reddy R, Johnson H, Ramsay JW, Carter SS. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993;341(8836):14-7.

Nawrocki JD, Bell TJ, Lawrence WT, Ward JP. A randomized controlled trial of transurethral microwave thermotherapy. Clinical Trial Br J Urol 1997;79(3):389-93. doi: 10.1046/j.1464-410x.1997.21515.x.

Ekstrand V, Westermark S, Wiksell H, Bergman B, Cronwall K. Longterm clinical outcome of transurethral microwave thermotherapy (TUMT) 1991–1999 at Karolinska Hospital, Sweden. Scand J Urol Nephrol 2002;36(2):113-8. doi: 10.1080/003655902753679391.

de La Rosette JJ, De Wildty MJ, Alvizatos, G. Transurethral microware thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994;44(1):58-63.

Aoun F, Quentin Marcelis Q, Roumeguère T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol 2015;7:125-36.

Saitz TR, Conlin MJC, Tessier CD, Hatch TR. Safety and efficaccy of transurethral microvawe therapy in high-risk catheter-dependent men. Turk J Urol 2019;45(1):27-30.

Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007;19(4):386-92.

Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R, et al. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl 2010;12(4):500-8.

Roehrborn CG, Nuckolls JG, Wei JT, Steers W. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int 2007;100(4):813-9.

Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357(8):762-74.

Abrams P. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. Letter. J Urol 2021;205(3):938. doi: 10.1097/JU.0000000000001558.

Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Hendersson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332(2):75-9. doi: 10.1056/NEJM199501123320202.

Oka AAG, Duarsa GKD, Novianti PA, Mahadewa TGB, Ryalino C. The impact of prostate-transurethral resection on erectile dysfunction in benign prostatic hyperplasia. Res Rep Urol 2019;11:91-6.

Storsky M, Jaeger I. BPH procedural treatment: the case for value based pay for performance. Adv Urol 2008;2008:954721.

Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FDR, Fourcade R, et al. The prevalence of male urinary incontinence in four centres: the UREPIK study. BJU Int 2003;92(9):943-7.

DiSantostefano RI, Biddle AK, Lavelle JP. The long term cost effectiveness of treatment for benign prostatic hyperplasia. Pharmacoeconomics 2006;24(2):171-91.

Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015;67(6):1066.

Gravas (Chair) S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of non-neurogenic male LUTS. European Association of Urology. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts (12.04.2021).

Chen S, Zhu L, Cai J, Zheng Z, Ge R, Wu M, et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with longterm results at 6 years. Eur Urol 2014;66(2014):284.

Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 2007;94(10):1201-8.

DOI: https://doi.org/10.21164/pomjlifesci.797

Copyright (c) 2021 Zbigniew Marek Ziętek

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/